Results 191 to 200 of about 580,459 (300)

Cells heal themselves: gene-edited hematopoietic stem cells restore frataxin deficiency in multiple organs. [PDF]

J Clin Invest
Osborne LR.
europepmc   +1 more source

A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial

British Journal of Haematology, EarlyView.
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne, Matthew A. Timmins, Charlotte Gaskell, Aimee Jackson, Clare Morland, Sonia Fox, Louise Hopkins, Nadia Nawaz, Susann Lehmann, Marc Wadsley, Caroline Cowley, Jacqueline Shaw, Naeem Khan, Nagesh Kalakonda, Christopher Trethewey, Ram Malladi, Paul Fields, Dima El Sharkawi, Michael Quinn, Nimish Shah, Andrew Davies, Kim Linton, Pam McKay, Rod Johnson, Simon D. Wagner, David Lewis, Graham P. Collins, Christopher P. Fox, Kate Cwynarski   +28 more
wiley   +1 more source

A new dawn for autologous haematopoietic stem cell transplantation in systemic sclerosis in the era of cellular therapies. [PDF]

J Scleroderma Relat Disord
Spierings J.
europepmc   +1 more source

CAR‐HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B‐cell non‐Hodgkin lymphoma

British Journal of Haematology, EarlyView.
High versus low baseline CAR‐HEMATOTOX scores were associated with poorer safety and efficacy outcomes in patients with R/R B‐NHL who received odronextamab in the ELM‐1 and ELM‐2 studies. The CAR‐HEMATOTOX score may provide a readily available measure for identifying patients at risk of inferior clinical outcomes with odronextamab treatment.
Matthew Matasar, David Tucker, Tae Min Kim, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Manjusha Namuduri, Aafia Chaudhry, Stefano Luminari   +9 more
wiley   +1 more source

Fresh (Non-cryopreserved) autologous stem cell transplantation in multiple myeloma: Faster engraftment and reduced hospitalization. [PDF]

Hematol Transfus Cell Ther
Kakci M, Öztürk OC, Şeker Ö, Basci S, Batgi H, Namdaroğlu S.   +5 more
europepmc   +1 more source

Temporal trends in infectious risk among multiple myeloma patients treated with daratumumab: A meta‐analysis

British Journal of Haematology, EarlyView.
Summary Anti‐cluster of differentiation 38 (Anti‐CD38) monoclonal antibodies such as daratumumab are widely used in multiple myeloma (MM), yet the timing and magnitude of infectious risk remain incompletely defined. We performed an individual patient‐level meta‐analysis of six randomized trials (N = 2989) comparing daratumumab‐ versus non‐daratumumab ...
Alissa Visram, Hira Mian, James Lee, Aaron Jones, Gregory R. Pond, Doris Hansen, Surbhi Sidana, Luciano J. Costa   +7 more
wiley   +1 more source

Enteral nutritional therapy practices in pediatric hematopoietic stem cell transplant centers in Brazil. [PDF]

Hematol Transfus Cell Ther
Viau VS, da Silva AF, Poloni S, Bosa VL, Behling EB.   +4 more
europepmc   +1 more source

Autologous Bone Marrow Transplantation in Hematology

Acta Clinica Belgica, 1987
openaire   +3 more sources